Hospital Acquired Infection Control Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The hospital-acquired infection control market is expected to witness a CAGR of 7.3% during the forecast period, 2022-2027.

The Covid-19 pandemic underlined the critical necessity of hand hygiene and the use of conventional infection control methods, as the World Health Organization and the Centers for Disease Control and Prevention (CDC) recommended, in reducing the number of hospital-acquired infections. During the Covid-19 epidemic, hospital-acquired infection (HAI) rates were reported to have decreased in healthcare settings. Journal of Family Medicine and Primary Care September 2021, by Mitra Manashij, the catheter-associated urinary tract infections (CAUTI) rates were reduced by 28.01%; the Central-line-associated bloodstream infections (CLABSI) rates declined by 37.61%, the surgical site infections (SSIs) rates reduced by 62.39%, while the highest ventilator-associated pneumonia (VAP) rates were reported in November 2019

Specific factors driving the market growth include increased hospital stays due to chronic diseases and surgeries, a rise in the incidences of different types of hospital-acquired infections, and innovative technologies implemented in devices that control infection.

Hospital-acquired infections are usually caused by pathogens, which spread quickly in the body. Due to the patients’ weak immune systems and poor conditions in a hospital, the infections spread faster than chronic infections. According to the Center for Diseases Control and Prevention, in 2021, approximately 75% of UTIs acquired in the hospital are linked to a urinary catheter. Urinary catheters are used by 15-25 percent of hospitalized patients during their stay. Additionally, 19,738 catheter-associated urinary tract infection cases were reported in the United States in 2020.

Similarly, according to the article published in Critical Care Medicine in March 2020 by Kalil, ventilator-associated pneumonia (VAP) was one of the most challenging infections before the coronavirus disease 2019 (COVID-19) pandemic. With the growing number of hospitals and ICUs being overburdened with the complex and prolonged acute care of COVID-19 patients, VAP has become a more significant issue during this pandemic, with an overall crude incidence ranging from 40% to 60%. Thus, increasing incidence of HAI is expected to boost the market studied.

The most common type of hospital-acquired infection is a urinary tract infection (UTI). The increase in incidences of different types of hospital-acquired conditions, innovative technologies implemented in devices that control disease, awareness regarding the use of personalized medicines, and cost-effective drugs to treat hospital-acquired infections are some factors driving the growth of the studied market.

Key Market Trends

Disinfectant is Expected to Hold Significant Market Share in the Product Type

Disinfection is a process that eliminates many or all pathogenic microorganisms, except the bacterial spores from inanimate objects. This is accomplished by the use of liquid chemicals or wet pasteurization. The efficiency of disinfection has been affected by several factors, each of which may limit the efficacy of the process.

The outbreak of COVID-19 has significantly impacted the growth of the disinfectant market. The usage of disinfectants that provide protection in healthcare facilities and safeguard personnel performing medical procedures that expose them to the virus is rising.​ As a result, several companies have now ramped up their production and are focusing on developing new products. In April 2020, ITC launched its product "Savlon Surface Disinfectant Spray." Thus, the demand for surface disinfectants is expected to increase during the COVID-19 pandemic.

The rising incidence of hospital-acquired infections, a growing senior population, and subsequent growth in the prevalence of chronic diseases and the increasing number of surgical procedures. As per the study titled "Healthcare-Associated InfectionsA New Pathology in Medical Practice?" published in February 2020, about 50% of hospital-acquired infections occur in the intensive care unit. Surface disinfectants play a crucial role in preventing these infections. Hence, with the growing burden of HAIs, the market is expected to grow over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

According to the Centers for Disease Control and Prevention (CDC) 2021, even though significant progress has been made in stopping some healthcare-associated infection types from spreading, there is still much more work to be done. On any given day, in the United States, around one in 31 hospital patients has at least one healthcare-associated infection. North America, especially the United States and Canada, has made significant progress toward the collective goal of abolishing these HAIs. As a result, healthcare in this region has become safer now than it was even ten years ago.

The rise in chronic diseases, such as cardiovascular diseases, requires an extended hospital stay. Hence, there is an increase in the number of cases of hospital-acquired infection in the country.​​ According to 2020 data by the American Health Association, there were approximately 36.2 million hospital admissions in 2019. Building upon this success and continuing to eliminate hospital-acquired infections is critical, contributing to the largest market share of North America.

According to the Center for Disease Control and Prevention, in 2021, about a 24% increase in central line bloodstream infection (CLABSI) and a 35% increase in Ventilator-Associated Event (VAE) between 2019-2020. Thus Increasing prevalence rate of hospital-acquired infection in the United States boosts the market growth in the region.

Competitive Landscape

The hospital-acquired infection control market is highly competitive and consists of several players. Companies like 3M Company, Becton, Dickinson and Company, Belimed AG, Biomerieux Sa, Cantel Medical, Ethicon, Getinge Group, Kimberly-Clark Corporation, Sterigenics International LLC, and Steris Corporation, among others, hold a substantial market share in the hospital-acquired infection control market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.